{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:34:41Z","timestamp":1786649681078,"version":"build-2736575974"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>Radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) represents a major clinical challenge due to its limited response to conventional treatment and poor prognosis. Peptide receptor radionuclide therapy (PRRT) has emerged as a promising treatment modality in patients with somatostatin receptor (SSTR)-positive tumors. We present an 82-year-old female patient with RAIR-DTC who underwent six cycles of PRRT after demonstrating SSTR positivity on Ga-68 DOTATATE positron emission tomography\/computed tomography. This case highlights the limited therapeutic efficacy of PRRT in RAIR-DTC, despite favorable imaging characteristics. It underscores the need for better patient selection and further research to clarify the role of PRRT in this population.<\/jats:p>","DOI":"10.4103\/njcp.njcp_538_25","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T03:00:25Z","timestamp":1774926025000},"page":"360-363","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Is Peptide Receptor Radionuclide Therapy Effective in the Treatment of Radioactive Iodine-Refractory Differentiated Thyroid Cancer?\u2014A Case Report"],"prefix":"10.4103","volume":"29","author":[{"given":"A","family":"\u00c7elik","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Pamukkale University Faculty of Medicine, Pamukkale, Denizli, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"\u015eeng\u00f6z","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Pamukkale University Faculty of Medicine, Pamukkale, Denizli, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"R1-20260416","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1530\/ERC-15-0445","article-title":"Recent incidences and differential trends of thyroid cancer in the USA","volume":"23","author":"Mao","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"R2-20260416","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(13)70215-8","article-title":"Definition and management of radioactive iodine-refractory differentiated thyroid cancer","volume":"2","author":"Schlumberger","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R3-20260416","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/RLU.0000000000003110","article-title":"Peptide receptor radionuclide therapy in patients with differentiated thyroid cancer: A meta-analysis","volume":"45","author":"Lee","year":"2020","journal-title":"Clin Nucl Med"},{"key":"R4-20260416","first-page":"1857","article-title":"Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines","volume":"82","author":"Ain","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"R5-20260416","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.beem.2017.04.012","article-title":"Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients","volume":"31","author":"Resteghini","year":"2017","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"R6-20260416","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2967\/jnumed.119.240945","article-title":"Appropriate use criteria for nuclear medicine in the evaluation and treatment of differentiated thyroid cancer","volume":"61","author":"Donohoe","year":"2020","journal-title":"J Nucl Med"},{"key":"R7-20260416","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.semnuclmed.2016.01.010","article-title":"Peptide receptor radionuclide therapy (PRRT) of medullary and nonmedullary thyroid cancer using radiolabeled somatostatin analogues","volume":"46","author":"Salavati","year":"2016","journal-title":"Semin Nucl Med"},{"key":"R8-20260416","doi-asserted-by":"crossref","first-page":"896287","DOI":"10.3389\/fendo.2022.896287","article-title":"Peptide receptor radionuclide therapy in thyroid cancer","volume":"13","author":"Gubbi","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R9-20260416","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s13139-020-00677-0","article-title":"Management impact of 68Ga-DOTATATE PET\/CT in neuroendocrine tumors","volume":"55","author":"Anderson","year":"2021","journal-title":"Nucl Med Mol Imaging"},{"key":"R10-20260416","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.3390\/cancers15174290","article-title":"Molecular theranostics in radioiodine-refractory differentiated thyroid cancer","volume":"15","author":"Petranovic Ovcaricek","year":"2023","journal-title":"Cancers (Basel)"}],"container-title":["Nigerian Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_538_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:57:01Z","timestamp":1786647421000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_538_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/njcp.njcp_538_25","relation":{},"ISSN":["1119-3077","2229-7731"],"issn-type":[{"value":"1119-3077","type":"print"},{"value":"2229-7731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"2025-08-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}